Paroxysmal dysarthria-ataxia syndrome

Area of Science:

• Neurology
• Neuroscience
• Clinical Medicine

Background:

• Paroxysmal dysarthria ataxia syndrome (PDAS) is characterized by recurrent, stereotyped episodes of ataxia and dysarthria.
• These episodes are often associated with lesions in the central nervous system, particularly the midbrain.
• Understanding the etiology and effective treatments for PDAS is crucial for patient management.

Observation:

• A case of a woman presenting with paroxysmal dysarthria and ataxia was observed.
• The patient's symptoms were found to be secondary to a lesion located in the midbrain.
• The clinical presentation included recurrent episodes of slurred speech, limb clumsiness, unsteady gait, and vertigo.

Findings:

• The midbrain lesion was identified as the cause of the paroxysmal dysarthria and ataxia in this patient.
• Treatment with carbamazepine was initiated to manage the recurrent neurological episodes.
• The patient experienced successful resolution of symptoms following carbamazepine treatment.

Implications:

• This case highlights carbamazepine as a potential therapeutic option for paroxysmal dysarthria ataxia syndrome.
• It underscores the importance of investigating midbrain lesions in patients presenting with these paroxysmal neurological symptoms.
• Further research may elucidate the precise mechanisms by which carbamazepine alleviates PDAS symptoms associated with midbrain pathology.